Silviu Itescu - CEO - Mesoblast
(ASX:MSB) is using its proprietary mesenchymal lineage cell technology platform to develop and commercialise innovative allogeneic cellular medicines to treat complex inflammatory diseases resistant to conventional standard of care.
